{"result": {"id": "b1e5235f-f2f9-4525-a722-6ec02c06bc11", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>POLYCYTHEMIA VERA (PV)<|>EVENT<|>A medical condition discussed in Ther Clin Risk Manag regarding emerging treatment options)  \n##\n(\"entity\"<|>MULTIPLE MYELOMA<|>EVENT<|>A cancer type studied in BMC Cancer and Int J Mol Sci for metabolic disorders)  \n##\n(\"entity\"<|>HYPERTENSION<|>EVENT<|>A medical condition central to the JNC7 report, ESC guidelines, and multiple telemonitoring studies)  \n##\n(\"entity\"<|>HERB-DH1 PIVOTAL TRIAL<|>EVENT<|>A clinical trial on digital therapeutics for hypertension published in Eur Heart J)  \n##\n(\"entity\"<|>HOME BP TRIAL<|>EVENT<|>A randomized controlled trial on digital hypertension management published in BMJ)  \n##\n(\"relationship\"<|>POLYCYTHEMIA VERA (PV)<|>THER CLIN RISK MANAG<|>Emerging treatments for PV were discussed in Ther Clin Risk Manag<|>8)  \n##\n(\"relationship\"<|>MULTIPLE MYELOMA<|>BMC CANCER<|>Metabolic syndrome in multiple myeloma was studied in BMC Cancer<|>8)  \n##\n(\"relationship\"<|>MULTIPLE MYELOMA<|>INT J MOL SCI<|>Metabolic disorders in multiple myeloma were studied in Int J Mol Sci<|>8)  \n##\n(\"relationship\"<|>HYPERTENSION<|>JNC7 REPORT<|>The JNC7 report established guidelines for hypertension management<|>9)  \n##\n(\"relationship\"<|>HYPERTENSION<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>The Society issued global hypertension practice guidelines<|>8)  \n##\n(\"relationship\"<|>HYPERTENSION<|>HERB-DH1 PIVOTAL TRIAL<|>The trial tested digital therapeutics for hypertension<|>8)  \n##\n(\"relationship\"<|>HYPERTENSION<|>HOME BP TRIAL<|>The trial evaluated digital interventions for hypertension control<|>8)  \n##\n(\"relationship\"<|>HERB-DH1 PIVOTAL TRIAL<|>EUR HEART J<|>The trial results were published in Eur Heart J<|>8)  \n##\n(\"relationship\"<|>HOME BP TRIAL<|>BMJ<|>The trial results were published in BMJ<|>8)  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559153, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 556, "prompt_tokens": 4818, "total_tokens": 5374, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 4736}, "prompt_cache_hit_tokens": 4736, "prompt_cache_miss_tokens": 82}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ythemia vera (PV) : updateonemergingtreatmentoptions[J]. TherClinRisk Manag,2021,17:209-221.\n[745]  MarkusE, TrestmanS, Cohen Y, etal. Componentsofmeta- bolic syndrome in patients with multiple myeloma and smolde- ring multiplemyeloma[J]. BMCCancer,2020,20(1) :489.\n[746]  GavriatopoulouM, PaschouSA, Ntanasis-StathopoulosI, etal. Metabolicdisordersinmultiplemyeloma[J]. IntJMolSci,2021, 22(21) :11430.\n[747]  Chobanian AV, Bakris GL, Black HR, etal.  The seventh re- portof the joint national committee on prevention, detection,  evaluation, and treatmentofhighbloodpressure: theJNC7 re- port[J]. JAMA,2003,289(19) :2560-2572.\n[748]  vandenBornBH, LipG, Brguljan-HitijJ, etal. ESC councilon hypertension positiondocumentonthemanagementofhyperten- sive emergencies[J].  Eur Heart J Cardiovasc Pharmacother,  2019,5(1) :37-46.\n[749]  VerdecchiaP, ReboldiG, AngeliF.  The2020InternationalSo- ciety ofHypertensionglobalhypertensionpracticeguidelines-key messagesandclinicalconsiderations[J]. EurJ InternMed,2020,  82:1-6.\n[750]  MokashiSA, Svensson LG.  Guidelines for the managementof thoracicaorticdiseasein2017[J]. Gen ThoracCardiovascSurg,\n\n\n2019,67(1) :59-65.\n[751]  国家卫生计生委.  国家基本公共卫生服务规范(第三版) [EB/ OL].  (2017-04-17) [2024-06-02].  http://www.  nhc. gov. cn/ ewebeditor/uploadfile/2017/04/20170417104506514. pdf.\n[752]  张丽芳 , 张立威.  我国实施竞争性基层首诊制度 SWOT分析 [J]. 中国社会医学杂志 ,2017,34(5) :426-428.\n[753]  颜梅 ,莫李婵 ,符岳 ,等.  基于“互联网 +”的高血压干预策略研究 [J]. 解放军预防医学杂志 ,2020,38(3) :55-58.\n[754]  Friedman RH, KazisLE, JetteA, etal.  A telecommunications system for monitoring and counseling patients with hyperten- sion.  Impactonmedicationadherenceandbloodpressurecontrol [J]. Am JHypertens,1996,9(4Pt1) :285-292.\n[755]  Green BB, Cook AJ, Ralston JD, etal.  Effectiveness ofhome blood pressure monitoring, Web communication, and pharma- cistcare on hypertension control: a randomized controlled trial [J]. JAMA,2008,299(24) :2857-2867.\n[756]  Fishman PA,  Cook AJ, Anderson ML, et al.  Improving BP controlthrough electroniccommunications: an economicevalua- tion[J]. Am JManagCare,2013,19(9) :709-716.\n[757]  KarioK, NomuraA, HaradaN, etal. Efficacyofadigitalther- apeutics system in the management of essential hypertension:  the HERB-DH1 pivotal trial[J]. Eur Heart J, 2021, 42(40) :  4111-4122.\n[758]  McManusRJ, LittleP, StuartB, etal.  HomeandOnlineMan- agementand Evaluation ofBloodPressure(HOME BP) using a digitalintervention in poorly controlled hypertension: random- ised controlledtrial[J]. BMJ,2021,372:m4858.\n[759]  YueJ, YangX, WangB, etal.  Homebloodpressuretelemoni- toring for improving blood pressure control in middle-aged and elderlypatientswithhypertension[J]. J Clin Hypertens(Green- wich) ,2021,23(9) :1744-1751.\n[760]  OmboniS, Gazzola T, CarabelliG, et al.  Clinicalusefulness and costeffectivenessofhomeblood pressure telemonitoring: meta- analysisofrandomized controlled studies[J]. J Hypertens,2013,  31(3) :455-468.\n[761]  Duan Y, Xie Z, Dong F, et al.  Effectiveness of home blood pressuretelemonitoring: a systematic review and meta-analysis ofrandomised controlled studies[J]. J Hum Hypertens,2017,31\n(7) :427-437.\n[762]  OmboniS, PanzeriE, Campolo L.  E-health in hypertension man- agement: an insight into the current and future role\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>THER CLIN RISK MANAG<|>ORGANIZATION<|>A journal publishing research on clinical risk management and therapeutics, including updates on emerging treatment options for conditions like polycythemia vera (PV))  \n##\n(\"entity\"<|>MARKUS E<|>PERSON<|>A researcher involved in studying metabolic syndrome components in patients with multiple myeloma and smoldering multiple myeloma)  \n##\n(\"entity\"<|>BMC CANCER<|>ORGANIZATION<|>A journal publishing research on cancer, including studies on metabolic disorders in multiple myeloma)  \n##\n(\"entity\"<|>GAVRIATOPOULOU M<|>PERSON<|>A researcher studying metabolic disorders in multiple myeloma)  \n##\n(\"entity\"<|>INT J MOL SCI<|>ORGANIZATION<|>A journal publishing research on molecular sciences, including metabolic disorders in multiple myeloma)  \n##\n(\"entity\"<|>CHOBIANIAN AV<|>PERSON<|>A researcher involved in the JNC7 report on hypertension prevention, detection, evaluation, and treatment)  \n##\n(\"entity\"<|>JNC7 REPORT<|>EVENT<|>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure)  \n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>A journal publishing the JNC7 report and other medical research)  \n##\n(\"entity\"<|>ESC COUNCIL ON HYPERTENSION<|>ORGANIZATION<|>A council providing guidelines on the management of hypertensive emergencies)  \n##\n(\"entity\"<|>EUR HEART J CARDIOVASC PHARMACOTHER<|>ORGANIZATION<|>A journal publishing research on cardiovascular pharmacotherapy, including hypertension management)  \n##\n(\"entity\"<|>VERDECCHIA P<|>PERSON<|>A researcher involved in the 2020 International Society of Hypertension global hypertension practice guidelines)  \n##\n(\"entity\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>ORGANIZATION<|>An organization providing global hypertension practice guidelines)  \n##\n(\"entity\"<|>EUR J INTERN MED<|>ORGANIZATION<|>A journal publishing research on internal medicine, including hypertension guidelines)  \n##\n(\"entity\"<|>MOKASHI SA<|>PERSON<|>A researcher involved in guidelines for the management of thoracic aortic disease)  \n##\n(\"entity\"<|>GEN THORAC CARDIOVASC SURG<|>ORGANIZATION<|>A journal publishing research on thoracic and cardiovascular surgery)  \n##\n(\"entity\"<|>NATIONAL HEALTH COMMISSION OF CHINA<|>ORGANIZATION<|>An organization publishing national basic public health service standards)  \n##\n(\"entity\"<|>ZHANG LIFANG<|>PERSON<|>A researcher analyzing the SWOT of competitive primary care systems in China)  \n##\n(\"entity\"<|>ZHANG LIWEI<|>PERSON<|>A co-author of the SWOT analysis on competitive primary care systems in China)  \n##\n(\"entity\"<|>YAN MEI<|>PERSON<|>A researcher studying internet-based hypertension intervention strategies)  \n##\n(\"entity\"<|>FRIEDMAN RH<|>PERSON<|>A researcher involved in telecommunications systems for hypertension monitoring and counseling)  \n##\n(\"entity\"<|>AM J HYPERTENS<|>ORGANIZATION<|>A journal publishing research on hypertension, including studies on medication adherence and blood pressure control)  \n##\n(\"entity\"<|>GREEN BB<|>PERSON<|>A researcher studying the effectiveness of home blood pressure monitoring and pharmacist care)  \n##\n(\"entity\"<|>JAMA<|>ORGANIZATION<|>A journal publishing research on hypertension control through randomized controlled trials)  \n##\n(\"entity\"<|>FISHMAN PA<|>PERSON<|>A researcher improving blood pressure control through electronic communications)  \n##\n(\"entity\"<|>AM J MANAG CARE<|>ORGANIZATION<|>A journal publishing research on managed care, including economic evaluations of hypertension management)  \n##\n(\"entity\"<|>KARIO K<|>PERSON<|>A researcher involved in the HERB-DH1 pivotal trial on digital therapeutics for hypertension)  \n##\n(\"entity\"<|>EUR HEART J<|>ORGANIZATION<|>A journal publishing research on cardiovascular health, including digital therapeutics for hypertension)  \n##\n(\"entity\"<|>MCMANUS RJ<|>PERSON<|>A researcher involved in the HOME BP trial using digital interventions for hypertension management)  \n##\n(\"entity\"<|>BMJ<|>ORGANIZATION<|>A journal publishing research on home and online management of blood pressure)  \n##\n(\"entity\"<|>YUE J<|>PERSON<|>A researcher studying home blood pressure telemonitoring for middle-aged and elderly patients)  \n##\n(\"entity\"<|>J CLIN HYPERTENS<|>ORGANIZATION<|>A journal publishing research on clinical hypertension, including telemonitoring studies)  \n##\n(\"entity\"<|>OMBONI S<|>PERSON<|>A researcher involved in meta-analyses of home blood pressure telemonitoring)  \n##\n(\"entity\"<|>J HYPERTENS<|>ORGANIZATION<|>A journal publishing research on hypertension, including meta-analyses of telemonitoring)  \n##\n(\"entity\"<|>DUAN Y<|>PERSON<|>A researcher conducting systematic reviews on home blood pressure telemonitoring)  \n##\n(\"entity\"<|>J HUM HYPERTENS<|>ORGANIZATION<|>A journal publishing research on human hypertension, including meta-analyses of telemonitoring)  \n##\n(\"relationship\"<|>MARKUS E<|>BMC CANCER<|>Markus E published research in BMC Cancer on metabolic syndrome in multiple myeloma<|>8)  \n##\n(\"relationship\"<|>GAVRIATOPOULOU M<|>INT J MOL SCI<|>Gavriatopoulou M published research in Int J Mol Sci on metabolic disorders in multiple myeloma<|>8)  \n##\n(\"relationship\"<|>CHOBIANIAN AV<|>JNC7 REPORT<|>Chobanian AV was involved in the JNC7 report on hypertension<|>9)  \n##\n(\"relationship\"<|>JNC7 REPORT<|>JAMA<|>The JNC7 report was published in JAMA<|>8)  \n##\n(\"relationship\"<|>VERDECCHIA P<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>Verdecchia P contributed to the 2020 International Society of Hypertension guidelines<|>8)  \n##\n(\"relationship\"<|>INTERNATIONAL SOCIETY OF HYPERTENSION<|>EUR J INTERN MED<|>The International Society of Hypertension guidelines were published in Eur J Intern Med<|>8)  \n##\n(\"relationship\"<|>MOKASHI SA<|>GEN THORAC CARDIOVASC SURG<|>Mokashi SA published guidelines in Gen Thorac Cardiovasc Surg<|>8)  \n##\n(\"relationship\"<|>ZHANG LIFANG<|>ZHANG LIWEI<|>Zhang Lifang and Zhang Liwei co-authored a SWOT analysis on primary care systems<|>7)  \n##\n(\"relationship\"<|>FRIEDMAN RH<|>AM J HYPERTENS<|>Friedman RH published research in Am J Hypertens on hypertension monitoring<|>8)  \n##\n(\"relationship\"<|>GREEN BB<|>JAMA<|>Green BB published research in JAMA on hypertension control<|>8)  \n##\n(\"relationship\"<|>KARIO K<|>EUR HEART J<|>Kario K published the HERB-DH1 trial in Eur Heart J<|>8)  \n##\n(\"relationship\"<|>MCMANUS RJ<|>BMJ<|>McManus RJ published the HOME BP trial in BMJ<|>8)  \n##\n(\"relationship\"<|>OMBONI S<|>J HYPERTENS<|>Omboni S published meta-analyses in J Hypertens on telemonitoring<|>8)  \n##\n(\"relationship\"<|>DUAN Y<|>J HUM HYPERTENS<|>Duan Y published a systematic review in J Hum Hypertens<|>8)  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_fb2776120b19e9de3b424e914c1b66b02961da4e2298abfb78e6a2da5483964a_v2"}